Biomemory Launches Early Access for DNA Shield DNA-Based Offline Data Protection Service

French company Biomemory has introduced DNA Shield, its first commercial managed service that stores highly critical data in synthetic DNA for long-term offline retention. The offering targets organizations seeking protection against cyber attacks, infrastructure changes, regulatory audits, AI advances, and quantum computing threats. Data undergoes encryption and encoding into synthetic DNA before being placed in managed offline storage, with recovery available only through a controlled, non-self-service process. Initial use cases include cryptographic key continuity, industrial intellectual property preservation, regulated integrity records, and sovereign golden records. The launch follows Biomemory’s March 2026 acquisition of Catalog Technologies assets in Boston and the July 2026 appointment of Laurent Guengant as CEO. DNA Shield is currently available through an Early Access Program as the first step in the company’s longer-term Molecular IT roadmap, which plans general data storage capabilities from 2029 onward.

Security-InsiderTranslated from German

Read at source

Biomemory has launched DNA Shield, its first commercial managed service designed to store particularly critical data offline in synthetic DNA for decades-long retention independent of active IT systems.

The service is initially offered through an Early Access Program and targets organizations that need a separate, air-gapped layer of protection against cyber attacks, organizational changes, infrastructure migrations, regulatory examinations, advances in artificial intelligence, and quantum computing.

Service Concept and Workflow

DNA Shield creates an offline security layer that is deliberately disconnected from network-accessible attack surfaces. The solution is intended for relatively small volumes of irreplaceable information. Data first passes through a secure onboarding process where the customer selects the material and performs encryption. DNA Shield then encodes the information into synthetic DNA, which is stored under managed physical custody. Recovery is intentionally non-routine and requires a controlled, operator-mediated process rather than self-service access.

Initial Use Cases

  • Continuity of key custody: long-term recovery of cryptographic keys even after personnel or provider changes, positioned as a complement to certified hardware security modules.
  • Industrial intellectual property: offline copies of proprietary formulations, processes, or design parameters.
  • Regulated integrity records: tamper-evident copies proving that critical records have remained unchanged since approval.
  • Sovereign storage and golden records: preservation of records intended to outlast the originating systems and organizations.

Company Developments

The product introduction follows two key corporate changes. In March 2026 Biomemory acquired the assets of Catalog Technologies, a Boston-based DNA data storage firm, adding a second production and research site alongside its Paris headquarters. In July 2026 the company appointed Laurent Guengant as CEO, citing his more than 30 years of experience in storage, telecommunications, and energy sectors.

Availability and Roadmap

DNA Shield is currently accessible only via the Early Access Program. It represents the first element of Biomemory’s multi-year Molecular IT roadmap. The company plans to expand the offering to general data storage beginning in 2029, with molecular search and data processing capabilities to follow later.

Meridian digestThe week's most consequential security stories, distilled into one briefing.See the digest

More in Other

Using rpcclient from the Samba Suite to Assess and Secure Active Directory Environments
Netscout 1H 2026 Report: High-Power DDoS Attacks Surge 1,286 Percent as Carpet-Bombing and Residential Proxies Rise
Hackers Raise Temperatures to 50°C in European Supermarket Refrigeration Systems